322 related articles for article (PubMed ID: 15565180)
1. Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy.
Jin F; Xie Z; Kuo CJ; Chung LW; Hsieh CL
Cancer Gene Ther; 2005 Mar; 12(3):257-67. PubMed ID: 15565180
[TBL] [Abstract][Full Text] [Related]
2. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
Hsieh CL; Gardner TA; Miao L; Balian G; Chung LW
Cancer Gene Ther; 2004 Feb; 11(2):148-55. PubMed ID: 14695756
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus-mediated delivery of a soluble form of the VEGF receptor Flk1 delays the growth of murine and human pancreatic adenocarcinoma in mice.
Tseng JF; Farnebo FA; Kisker O; Becker CM; Kuo CJ; Folkman J; Mulligan RC
Surgery; 2002 Nov; 132(5):857-65. PubMed ID: 12464871
[TBL] [Abstract][Full Text] [Related]
4. Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy.
Thorne SH; Tam BY; Kirn DH; Contag CH; Kuo CJ
Mol Ther; 2006 May; 13(5):938-46. PubMed ID: 16469543
[TBL] [Abstract][Full Text] [Related]
5. Adenoviral vectors expressing human endostatin-angiostatin and soluble Tie2: enhanced suppression of tumor growth and antiangiogenic effects in a prostate tumor model.
Raikwar SP; Temm CJ; Raikwar NS; Kao C; Molitoris BA; Gardner TA
Mol Ther; 2005 Dec; 12(6):1091-100. PubMed ID: 16169279
[TBL] [Abstract][Full Text] [Related]
6. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW
Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044
[TBL] [Abstract][Full Text] [Related]
7. New targets for therapy in prostate cancer: modulation of stromal-epithelial interactions.
Chung LW; Hsieh CL; Law A; Sung SY; Gardner TA; Egawa M; Matsubara S; Zhau HE
Urology; 2003 Nov; 62(5 Suppl 1):44-54. PubMed ID: 14607217
[TBL] [Abstract][Full Text] [Related]
8. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
Wang H; Wei F; Li H; Ji X; Li S; Chen X
Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
[TBL] [Abstract][Full Text] [Related]
9. A novel targeting modality to enhance adenoviral replication by vitamin D(3) in androgen-independent human prostate cancer cells and tumors.
Hsieh CL; Yang L; Miao L; Yeung F; Kao C; Yang H; Zhau HE; Chung LW
Cancer Res; 2002 Jun; 62(11):3084-92. PubMed ID: 12036918
[TBL] [Abstract][Full Text] [Related]
10. Co-Targeting Prostate Cancer Epithelium and Bone Stroma by Human Osteonectin-Promoter-Mediated Suicide Gene Therapy Effectively Inhibits Androgen-Independent Prostate Cancer Growth.
Sung SY; Chang JL; Chen KC; Yeh SD; Liu YR; Su YH; Hsueh CY; Chung LW; Hsieh CL
PLoS One; 2016; 11(4):e0153350. PubMed ID: 27054343
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy of prostate cancer with the soluble vascular endothelial growth factor receptor Flk1.
Becker CM; Farnebo FA; Iordanescu I; Behonick DJ; Shih MC; Dunning P; Christofferson R; Mulligan RC; Taylor GA; Kuo CJ; Zetter BR
Cancer Biol Ther; 2002; 1(5):548-53. PubMed ID: 12496487
[TBL] [Abstract][Full Text] [Related]
12. Conditionally replicating adenovirus therapy utilizing bone sialoprotein promoter (Ad-BSP-E1a) in an in vivo study of treating androgen-independent intraosseous prostate cancer.
Li Y; Kacka M; Thompson M; Hsieh JT; Koeneman KS
Urol Oncol; 2011; 29(6):624-33. PubMed ID: 19963408
[TBL] [Abstract][Full Text] [Related]
13. Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas.
Kaliberov SA; Kaliberova LN; Buchsbaum DJ
Gene Ther; 2005 Mar; 12(5):407-17. PubMed ID: 15616600
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer.
Kubo H; Gardner TA; Wada Y; Koeneman KS; Gotoh A; Yang L; Kao C; Lim SD; Amin MB; Yang H; Black ME; Matsubara S; Nakagawa M; Gillenwater JY; Zhau HE; Chung LW
Hum Gene Ther; 2003 Feb; 14(3):227-41. PubMed ID: 12639303
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D3-inducible mesenchymal stem cell-based delivery of conditionally replicating adenoviruses effectively targets renal cell carcinoma and inhibits tumor growth.
Hsiao WC; Sung SY; Liao CH; Wu HC; Hsieh CL
Mol Pharm; 2012 May; 9(5):1396-408. PubMed ID: 22480282
[TBL] [Abstract][Full Text] [Related]
16. E10A, an adenovirus carrying human endostatin gene, in combination with docetaxel treatment inhibits prostate cancer growth and metastases.
Zhao P; Luo R; Wu J; Xie F; Li H; Xiao X; Fu L; Zhu X; Liu R; Zhu Y; Liang Z; Huang W
J Cell Mol Med; 2010 Jan; 14(1-2):381-91. PubMed ID: 26065034
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effects of viral vector-mediated antiangiogenic gene transfer in malignant ascites.
Hampl M; Tanaka T; Albert PS; Lee J; Ferrari N; Fine HA
Hum Gene Ther; 2001 Sep; 12(14):1713-29. PubMed ID: 11560766
[TBL] [Abstract][Full Text] [Related]
18. Replication-competent Ad11p vector (RCAd11p) efficiently transduces and replicates in hormone-refractory metastatic prostate cancer cells.
Sandberg L; Papareddy P; Silver J; Bergh A; Mei YF
Hum Gene Ther; 2009 Apr; 20(4):361-73. PubMed ID: 19199789
[TBL] [Abstract][Full Text] [Related]
19. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model.
Ko SC; Gotoh A; Thalmann GN; Zhau HE; Johnston DA; Zhang WW; Kao C; Chung LW
Hum Gene Ther; 1996 Sep; 7(14):1683-91. PubMed ID: 8886839
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.
Izawa JI; Sweeney P; Perrotte P; Kedar D; Dong Z; Slaton JW; Karashima T; Inoue K; Benedict WF; Dinney CP
Clin Cancer Res; 2002 Apr; 8(4):1258-70. PubMed ID: 11948141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
